TapewireFind a company

person · Reporting owner

Nguyen AnhCo

Disclosed activity across 1 company

Tapewire entity
19394
SEC CIK
0001977970

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Atara Biotherapeutics, Inc.ATRA · Entity 6828Director · President and CEOAugust 17, 2026August 26, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Atara Biotherapeutics, Inc.

Report date August 17, 2026 · Filed August 26, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect132,775 Reported balance After 2026-08-17 transaction · row 1
1 source row

Row 1 · 2026-08-17 · Sale · Disposed 5,062 · Balance 132,775

F1: Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement.

F2: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on August 17, 2026, on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees.

Filing footnotes · ownership attribution and instrument terms

F1: Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement.

F2: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on August 17, 2026, on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
August 17, 2026 Filed Aug 26, 2026 23:45 UTC Atara Biotherapeutics, Inc. ATRA · Entity 6828 SaleCommon Stock 5,062 $8.08 $40,882.74
Disclosure

SEC source: 0000905148-26-003960 · form4.xml · nonDerivative · entry 1

Nguyen AnhCo · CIK 0001977970 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 132,775

F1 · kind: Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement.

F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on August 17, 2026, on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees.

Read SEC document
May 18, 2026 Filed May 20, 2026 21:24 UTC Atara Biotherapeutics, Inc. ATRA · Entity 6828 SaleCommon Stock 5,241 $9.13 $47,844.56
Disclosure

SEC source: 0000905148-26-002571 · form4.xml · nonDerivative · entry 1

Nguyen AnhCo · CIK 0001977970 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 137,837

F1 · kind: Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement.

F2 · price: Represents the weighted average price. The shares were sold in multiple transactions at prices ranging from $9.12 to $9.40, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Read SEC document
March 09, 2026 Filed Mar 11, 2026 21:46 UTC Atara Biotherapeutics, Inc. ATRA · Entity 6828 GrantCommon Stock 81,100 $0.00 $0.00
Disclosure

SEC source: 0000905148-26-001225 · form4.xml · nonDerivative · entry 1

Nguyen AnhCo · CIK 0001977970 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 143,078

F1 · shares: These restricted stock units ("RSUs") vest as to 1/8th of the total number of shares (rounded down to the next whole number of shares) on the second Quarterly Vesting Date (as defined below) following March 9, 2026, and as to 1/8th of the total number of shares (rounded down to the next whole number of shares) on the next seven Quarterly Vesting Dates, such that all of the shares subject to the RSUs shall be vested on the last Quarterly Vesting Date, subject to the reporting person's continuous employment. "Quarterly Vesting Date" means March 1, May 15, August 15, and November 15 of each year, provided that if such date falls on a weekend or holiday, the Quarterly Vesting Date shall be the first business day after such date.

Read SEC document
March 02, 2026 Filed Mar 4, 2026 21:28 UTC Atara Biotherapeutics, Inc. ATRA · Entity 6828 SaleCommon Stock 1,442 $5.09 $7,335.45
Disclosure

SEC source: 0000905148-26-001143 · form4.xml · nonDerivative · entry 4

Nguyen AnhCo · CIK 0001977970 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 61,978

F1 · kind: Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement.

F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on March 2, 2026 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees.

Read SEC document
March 02, 2026 Filed Mar 4, 2026 21:28 UTC Atara Biotherapeutics, Inc. ATRA · Entity 6828 SaleCommon Stock 1,298 $5.09 $6,601.63
Disclosure

SEC source: 0000905148-26-001143 · form4.xml · nonDerivative · entry 3

Nguyen AnhCo · CIK 0001977970 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 63,420

F1 · kind: Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement.

F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on March 2, 2026 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees.

Read SEC document
March 02, 2026 Filed Mar 4, 2026 21:28 UTC Atara Biotherapeutics, Inc. ATRA · Entity 6828 SaleCommon Stock 58 $5.08 $294.64
Disclosure

SEC source: 0000905148-26-001143 · form4.xml · nonDerivative · entry 2

Nguyen AnhCo · CIK 0001977970 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 64,718

F1 · kind: Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement.

F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on March 2, 2026 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees.

Read SEC document
March 02, 2026 Filed Mar 4, 2026 21:28 UTC Atara Biotherapeutics, Inc. ATRA · Entity 6828 SaleCommon Stock 198 $5.08 $1,005.64
Disclosure

SEC source: 0000905148-26-001143 · form4.xml · nonDerivative · entry 1

Nguyen AnhCo · CIK 0001977970 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 64,776

F1 · kind: Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement.

F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on March 2, 2026 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees.

Read SEC document
November 17, 2025 Filed Nov 19, 2025 21:55 UTC Atara Biotherapeutics, Inc. ATRA · Entity 6828 SaleCommon Stock 56 $13.19 $738.53
Disclosure

SEC source: 0000905148-25-004141 · form4.xml · nonDerivative · entry 2

Nguyen AnhCo · CIK 0001977970 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 64,974

F1 · kind: Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement.

F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on November 17, 2025 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees.

Read SEC document
November 17, 2025 Filed Nov 19, 2025 21:55 UTC Atara Biotherapeutics, Inc. ATRA · Entity 6828 SaleCommon Stock 2,859 $13.19 $37,698.77
Disclosure

SEC source: 0000905148-25-004141 · form4.xml · nonDerivative · entry 1

Nguyen AnhCo · CIK 0001977970 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 65,030

F1 · kind: Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement.

F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on November 17, 2025 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees.

Read SEC document
August 18, 2025 Filed Aug 20, 2025 20:11 UTC Atara Biotherapeutics, Inc. ATRA · Entity 6828 SaleCommon Stock 1,620 $11.62 $18,819.54
Disclosure

SEC source: 0000905148-25-003070 · form4.xml · nonDerivative · entry 3

Nguyen AnhCo · CIK 0001977970 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 67,889

F1 · kind: Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement.

F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on August 18, 2025 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees.

Read SEC document
August 18, 2025 Filed Aug 20, 2025 20:11 UTC Atara Biotherapeutics, Inc. ATRA · Entity 6828 SaleCommon Stock 1,281 $11.62 $14,878.82
Disclosure

SEC source: 0000905148-25-003070 · form4.xml · nonDerivative · entry 2

Nguyen AnhCo · CIK 0001977970 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 69,509

F1 · kind: Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement.

F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on August 18, 2025 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees.

Read SEC document
August 18, 2025 Filed Aug 20, 2025 20:11 UTC Atara Biotherapeutics, Inc. ATRA · Entity 6828 SaleCommon Stock 57 $11.61 $661.94
Disclosure

SEC source: 0000905148-25-003070 · form4.xml · nonDerivative · entry 1

Nguyen AnhCo · CIK 0001977970 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 70,790

F1 · kind: Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement.

F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on August 18, 2025 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees.

Read SEC document
May 16, 2025 Filed May 20, 2025 20:58 UTC Atara Biotherapeutics, Inc. ATRA · Entity 6828 SaleCommon Stock 3,276 $6.76 $22,155.59
Disclosure

SEC source: 0000905148-25-001865 · form4.xml · nonDerivative · entry 1

Nguyen AnhCo · CIK 0001977970 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 70,847

F1 · kind: Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement.

F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on May 16, 2025 and May 19, 2025 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees.

Read SEC document
March 03, 2025 Filed Mar 5, 2025 22:17 UTC Atara Biotherapeutics, Inc. ATRA · Entity 6828 SaleCommon Stock 3,331 $7.00 $23,307.01
Disclosure

SEC source: 0000905148-25-000865 · form4.xml · nonDerivative · entry 1

Nguyen AnhCo · CIK 0001977970 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 74,123

F1 · kind: Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement.

F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on March 3, 2025 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees.

Read SEC document
November 18, 2024 Filed Nov 20, 2024 23:04 UTC Atara Biotherapeutics, Inc. ATRA · Entity 6828 SaleCommon Stock 1,664 $11.20 $18,633.47
Disclosure

SEC source: 0000905148-24-003241 · form4.xml · nonDerivative · entry 1

Nguyen AnhCo · CIK 0001977970 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 77,454

F1 · kind: Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement.

F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on November 18, 2024 and November 19, 2024 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees.

Read SEC document
September 09, 2024 Filed Sep 11, 2024 21:03 UTC Atara Biotherapeutics, Inc. ATRA · Entity 6828 GrantCommon Stock 45,000 $0.00 $0.00
Disclosure

SEC source: 0000905148-24-002545 · form4.xml · nonDerivative · entry 1

Nguyen AnhCo · CIK 0001977970 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 79,118

F1 · shares: These restricted stock units ("RSUs") vest as to 1/12th of the total number of shares (rounded down to the next whole number of shares) on the second Quarterly Vesting Date (as defined below) following September 9, 2024, and as to 1/12th of the total number of shares (rounded down to the next whole number of shares) on each of the next eleven Quarterly Vesting Dates, such that all of the shares subject to the RSUs on the grant date shall be vested on the last Quarterly Vesting Date, subject to the reporting person's continuous service. "Quarterly Vesting Date" means March 1, May 15, August 15, and November 15 of each year, provided that if such date falls on a weekend or holiday, the Quarterly Vesting Date shall be the first business day after such date.

Read SEC document
August 16, 2024 Filed Aug 20, 2024 22:27 UTC Atara Biotherapeutics, Inc. ATRA · Entity 6828 SaleCommon Stock 56 $6.63 $371.34
Disclosure

SEC source: 0000905148-24-002305 · form4.xml · nonDerivative · entry 3

Nguyen AnhCo · CIK 0001977970 · EVP, Chief Sci. & Tech Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 34,118

F1 · kind: Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement.

F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on August 16, 2024 and August 19, 2024 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees.

Read SEC document
August 16, 2024 Filed Aug 20, 2024 22:27 UTC Atara Biotherapeutics, Inc. ATRA · Entity 6828 SaleCommon Stock 297 $6.63 $1,969.11
Disclosure

SEC source: 0000905148-24-002305 · form4.xml · nonDerivative · entry 2

Nguyen AnhCo · CIK 0001977970 · EVP, Chief Sci. & Tech Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 34,174

F1 · kind: Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement.

F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on August 16, 2024 and August 19, 2024 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees.

Read SEC document
August 16, 2024 Filed Aug 20, 2024 22:27 UTC Atara Biotherapeutics, Inc. ATRA · Entity 6828 SaleCommon Stock 1,468 $6.63 $9,731.37
Disclosure

SEC source: 0000905148-24-002305 · form4.xml · nonDerivative · entry 1

Nguyen AnhCo · CIK 0001977970 · EVP, Chief Sci. & Tech Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 34,471

F1 · kind: Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement.

F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on August 16, 2024 and August 19, 2024 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees.

F3 · balance_after: This amount reflects the 1:25 reverse stock split effected by the Issuer on June 20, 2024.

Read SEC document
May 16, 2024 Filed May 21, 2024 00:34 UTC Atara Biotherapeutics, Inc. ATRA · Entity 6828 SaleCommon Stock 42,899 $0.62 $26,468.68
Disclosure

SEC source: 0000905148-24-001560 · form4.xml · nonDerivative · entry 1

Nguyen AnhCo · CIK 0001977970 · EVP, Chief Sci. & Tech Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 898,498

F1 · kind: Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement.

F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on May 16, 2024 and May 17, 2024 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees.

Read SEC document
March 04, 2024 Filed Mar 6, 2024 23:18 UTC Atara Biotherapeutics, Inc. ATRA · Entity 6828 SaleCommon Stock 10,746 $0.72 $7,737.12
Disclosure

SEC source: 0000905148-24-000910 · form4.xml · nonDerivative · entry 1

Nguyen AnhCo · CIK 0001977970 · EVP, Chief Sci. & Tech Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 941,397

F1 · kind: Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement.

F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on March 4, 2024 and March 5, 2024 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees.

Read SEC document
January 08, 2024 Filed Jan 9, 2024 21:40 UTC Atara Biotherapeutics, Inc. ATRA · Entity 6828 GrantCommon Stock 675,000 $0.00 $0.00
Disclosure

SEC source: 0000905148-24-000114 · form4.xml · nonDerivative · entry 1

Nguyen AnhCo · CIK 0001977970 · EVP, Chief Sci. & Tech Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 952,143

F1 · shares: These restricted stock units vest as to 1/8th of the total number of shares (rounded down to the next whole number of shares) on the second Quarterly Vesting Date (as defined below) following January 8, 2024, and as to 1/8th of the total number of shares (rounded down to the next whole number of shares) on the next seven Quarterly Vesting Dates, such that all of the shares shall be vested on the last Quarterly Vesting Date, subject to the reporting person's continuous service. "Quarterly Vesting Date" means March 1, May 15, August 15, and November 15 of each year, provided that if such date falls on a weekend or holiday, the Quarterly Vesting Date shall be the first business day after such date.

Read SEC document
November 16, 2023 Filed Nov 20, 2023 22:31 UTC Atara Biotherapeutics, Inc. ATRA · Entity 6828 SaleCommon Stock 8,856 $0.39 $3,444.98
Disclosure

SEC source: 0000905148-23-001512 · form4.xml · nonDerivative · entry 1

Nguyen AnhCo · CIK 0001977970 · EVP, Chief Sci. & Tech Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 277,143

F1 · kind: Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement.

F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on November 16, 2023 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employee.

Read SEC document
August 16, 2023 Filed Aug 18, 2023 22:25 UTC Atara Biotherapeutics, Inc. ATRA · Entity 6828 SaleCommon Stock 9,277 $1.65 $15,334.88
Disclosure

SEC source: 0001140361-23-040561 · form4.xml · nonDerivative · entry 2

Nguyen AnhCo · CIK 0001977970 · EVP, Chief Sci. & Tech Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 285,999

F1 · kind: Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement.

F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on August 16, 2023 and August 17, 2023 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employee.

Read SEC document
August 16, 2023 Filed Aug 18, 2023 22:25 UTC Atara Biotherapeutics, Inc. ATRA · Entity 6828 SaleCommon Stock 5,849 $1.65 $9,662.55
Disclosure

SEC source: 0001140361-23-040561 · form4.xml · nonDerivative · entry 1

Nguyen AnhCo · CIK 0001977970 · EVP, Chief Sci. & Tech Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 295,276

F1 · kind: Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement.

F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on August 16, 2023 and August 17, 2023 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employee.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.